Premium
Defining an optimal time window to screen for hepatoblastoma in children with Beckwith‐Wiedemann syndrome
Author(s) -
Mussa Alessandro,
Duffy Kelly A.,
Carli Diana,
Ferrero Giovanni Battista,
Kalish Jennifer M.
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27492
Subject(s) - hepatoblastoma , beckwith–wiedemann syndrome , medicine , pediatrics , cohort , epidemiology , genetics , gene expression , biology , dna methylation , gene
Patients with Beckwith‐Wiedemann spectrum (BWSp) undergo quarterly alpha‐fetoprotein measurement for hepatoblastoma (HB) screening up to 4 years of age, paralleling the epidemiology of nonsyndromic HB. However, specific data on the timing of HB development in BWSp are lacking. Here we compare the timing of presentation of HBs in BWSp with a control cohort of consecutive HB cases, demonstrating that halving screening duration of screening procedures in BWSp likely will not impact its effectiveness.